Isradipine--a calcium channel blocker--does not potentiate chloroquine antiplasmodial activity against Plasmodium falciparum.
Culturing fresh clinical isolates of P. falciparum and using the isotopic method, we tested separately chloroquine and isradipine--a calcium channel blocker--, and also the combination isradipine plus chloroquine. Tested wild isolates were chloroquine-sensitive. With regard to the combination isradipine/chloroquine, the isobolograms obtained indicate that isradipine antagonises chloroquine antiplasmodial activity. Taking into account these findings, we discuss the issues related to the calcium channel blocker molecules.
Randrianarivelojosia
M
M
Groupe de Recherche sur le Paludisme, Institut Pasteur de Madagascar, Antananarivo. milijaon@pasteur.mg
Jambou
R
R
D000818:Animals; D000962:Antimalarials / Q000494:pharmacology*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D002738:Chloroquine / Q000494:pharmacology*; D004351:Drug Resistance; D004357:Drug Synergism; D006801:Humans; D017275:Isradipine / Q000494:pharmacology*; D008270:Madagascar; D016778:Malaria, Falciparum / Q000188:drug therapy; D021261:Parasitic Sensitivity Tests; D010963:Plasmodium falciparum / Q000187:drug effects*
D000962:Antimalarials; D002121:Calcium Channel Blockers; D002738:Chloroquine; D017275:Isradipine